Trial
NCT02855268
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Alport Syndrome
Intervention
lademirsen (SAR339375)
Why stopped
The results of the futility analysis led to the study termination. No unexpected safety findings were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-11